StockData
Abeona Therapeutics Inc. logo

Abeona Therapeutics Inc. (ABEO) stock

ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/3024% below fair value
$2.73+0.13 (+5.00%)

Close on Nov 18, 2026Market cap $156.11MP/E –Yield –

Abeona Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Abeona Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$81.53M. For fiscal 2025 it was -$84.30M. The highest annual figure on record is -$1.00K in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$84.30M–
FY2024Dec 31, 2024-$58.46M–
FY2023Dec 31, 2023-$37.34M–
FY2022Dec 31, 2022-$43.61M–
FY2021Dec 31, 2021-$69.82M–
FY2020Dec 31, 2020-$36.36M–
FY2019Dec 31, 2019-$69.13M–
FY2018Dec 31, 2018-$48.35M–
FY2017Dec 31, 2017-$23.52M–
FY2016Dec 31, 2016-$13.53M–
FY2015Dec 31, 2015-$10.73M–
FY2014Dec 31, 2014-$1.61M–
FY2013Dec 31, 2013-$1.00K–
FY2012Dec 31, 2012-$3.97M–
FY2011Dec 31, 2011-$7.65M–
FY2010Dec 31, 2010-$6.87M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.98M–
Q1 FY2026Mar 31, 2026-$20.74M–
Q4 FY2025Dec 31, 2025-$19.11M–
Q3 FY2025Sep 30, 2025-$23.71M–
Q2 FY2025Jun 30, 2025-$21.69M–
Q1 FY2025Mar 31, 2025-$19.80M–
Q4 FY2024Dec 31, 2024-$17.17M–
Q3 FY2024Sep 30, 2024-$12.64M–
Q2 FY2024Jun 30, 2024-$13.40M–
Q1 FY2024Mar 31, 2024-$15.26M–
Q4 FY2023Dec 31, 2023-$9.27M–
Q3 FY2023Sep 30, 2023-$5.79M–
Q2 FY2023Jun 30, 2023-$10.32M–
Q1 FY2023Mar 31, 2023-$11.96M–
Q4 FY2022Dec 31, 2022-$14.02M–
Q3 FY2022Sep 30, 2022-$6.79M–
Q2 FY2022Jun 30, 2022-$9.01M–
Q1 FY2022Mar 31, 2022-$13.79M–
Q4 FY2021Dec 31, 2021-$33.51M–
Q3 FY2021Sep 30, 2021-$10.74M–
Q2 FY2021Jun 30, 2021-$11.55M–
Q1 FY2021Mar 31, 2021-$14.03M–
Q4 FY2020Dec 31, 2020-$1.64M–
Q3 FY2020Sep 30, 2020-$10.97M–
Q2 FY2020Jun 30, 2020-$10.03M–
Q1 FY2020Mar 31, 2020-$13.71M–
Q4 FY2019Dec 31, 2019-$14.37M–
Q3 FY2019Sep 30, 2019-$19.19M–
Q2 FY2019Jun 30, 2019-$19.27M–
Q1 FY2019Mar 31, 2019-$16.30M–
Q4 FY2018Dec 31, 2018-$17.63M–
Q3 FY2018Sep 30, 2018-$10.70M–
Q2 FY2018Jun 30, 2018-$12.44M–
Q1 FY2018Mar 31, 2018-$7.58M–
Q4 FY2017Dec 31, 2017-$5.75M–
Q3 FY2017Sep 30, 2017-$6.84M–
Q2 FY2017Jun 30, 2017-$4.99M–
Q1 FY2017Mar 31, 2017-$5.93M–
Q4 FY2016Dec 31, 2016-$3.41M–
Q3 FY2016Sep 30, 2016-$4.14M–

More Abeona Therapeutics figures

See a number that looks wrong?